Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients PBMCs: Potential role for STAT-3 and NF-B signaling

Abstract

Curcumin inhibits cell growth and induces apoptosis in a number of tumor cell lines and animal models. Human clinical trials indicated no dose-limiting toxicity when administered at doses up to 8 g per day. The purpose of this study was to address the antitumor effect of curcumin on cutaneous T-cell lymphoma (CTCL) cell lines and peripheral blood mononuclear cells (PBMCs) from patients with CTCL compared with healthy donors controls. Curcumin at 5-20 M for 24 and 48 hours induced apoptosis in a time- and dose-dependent manner in three CTCL cell lines (namely MJ, Hut78, and HH). Curcumin at 5-20 M for 48 hours also caused more apoptosis in patients PBMCs compared with healthy donors PBMCs (P0.05). Curcumin decreased protein and mRNA expression levels of signal transducer and activator of transcription (STAT)-3, bcl-2, and survivin in three cell lines and in patients PBMCs. Curcumin inhibited STAT-3 and IB-α phosphorylation, as well as suppressed DNA binding of nuclear factor (NF)-B in these cells. Caspase-3 was activated and poly (ADP-Ribose) polymerase was cleaved after curcumin treatment. These data suggest that curcumin selectively induces apoptosis in association with the downregulation of STAT-3 and NF-B signaling pathways in CTCL cells. Our findings provide a mechanistic rationale for the potential use of curcumin as a therapeutic agent for patients with CTCL. © 2010 The Society for Investigative Dermatology.